Table 3.
Associations [OR (95%CI)] of 1-SD increases in baseline arsenic exposure variables with PR and QRS prolongation measured during follow-up.a
| Variable | PR prolongation | QRS prolongation | ||
|---|---|---|---|---|
| OR (95% CI) | pTrend | OR (95% CI) | pTrend | |
| Well-water arsenic (µg/L)b | ||||
| Model 1c | 0.94 (0.68, 1.28) | 0.67 | 1.15 (0.94, 1.41) | 0.17 |
| Model 2d | 0.88 (0.63, 1.22) | 0.44 | 1.12 (0.90, 1.39) | 0.31 |
| Model 3e | 0.96 (0.68, 1.36) | 0.83 | 1.09 (0.86, 1.37) | 0.48 |
| Urinary arsenic (µg/g creatinine)b | ||||
| Model 1c | 0.72 (0.45, 1.14) | 0.16 | 1.06 (0.87, 1.29) | 0.56 |
| Model 2d | 0.69 (0.42, 1.11) | 0.12 | 1.11 (0.91, 1.35) | 0.29 |
| Model 3e | 0.80 (0.47, 1.37) | 0.41 | 1.09 (0.76, 1.57) | 0.63 |
| aA PR interval of > 200 msec was considered PR prolongation; a QRS interval of ≥ 120 msec was considered QRS prolongation. bORs for a 1-SD increase in well-water arsenic (108.7 µg/L) and urinary arsenic (270.7 µg/g creatinine). n (cases/noncases) for PR prolongation analyses was 45/1,660 and 43/1,604 for well-water and urinary arsenic, respectively; n (cases/noncases) for QRS prolongation analyses was 84/1,622 and 79/1,569 for well-water and urinary arsenic, respectively. cAdjusted for sex and age (years). dAdjusted for model 1 variables plus BMI, smoking status (never, past, and current), and educational attainment (years). eAdjusted for model 2 variables plus changes in urinary arsenic (µg/g creatinine) between visits. | ||||